Postnatal brain development and psychotropic drugs. Effects on animals and animal models of depression and attention-deficit/hyperactivity disorder

Current Pharmaceutical Design

Volumn 16, Issue 22, 2010, Pages 2474-2483

  Bock, Nathalie ^a   Gerlach, Manfred ^b   Rothenberger, Aribert ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

ADHD; Animals; Antidepressants; Brain development; Depression; SSRIs; Stimulants

Indexed keywords

AMPHETAMINE; ATOMOXETINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; METHYLPHENIDATE; REBOXETINE; TIANEPTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ATTENTION DEFICIT DISORDER; BRAIN DEVELOPMENT; DEPRESSION; MOUSE; NONHUMAN; POSTNATAL CARE; PRIORITY JOURNAL; RAT; REVIEW;

AGING; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; PSYCHOTROPIC DRUGS;

EID: 77955641197     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791959836     Document Type: Review

References (90)

1. Parens E, Johnston J. Understanding the agreements and controversies surrounding childhood psychopharmacology. Child Adolesc Psychiatr Ment Health 2008; 2(1): 5.
2. Fanton J, Gleason MM. Psychopharmacology and preschoolers: a critical review of current conditions. Child Adolesc Psychiatr Clin N Am 2009; 18(3): 753-71.
3. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 2009; 19(9): 629-35.
4. Spetie L, Arnold LE. Ethical issues in child psychopharmacology research and practice: emphasis on preschoolers. Psychopharmacology (Berl) 2007; 191(1): 15-26.
5. Mitchell B, Carleton B, Smith A, et al. Trends in psychostimulant and antidepressant use by children in 2 Canadian provinces. Can J Psychiatry 2008; 53(3): 152-9.
6. Willoughby MT. Developmental course of ADHD symptomatology during the transition from childhood to adolescence: a review with recommendations. J Child Psychol Psychiatry 2003; 44(1): 88-106.
7. Kovacs M. Presentation and course of major depressive disorder during childhood and later years of the life span. J Am Acad Child Adolesc Psychiatry 1996; 35(6): 705-15.
8. Leckman JF. Phenomenology of tics and natural history of tic disorders. Brain Dev 2003; 25 (Suppl 1): S24-8.
9. Steinhausen HC, Rothenberger A, Döpfner M. Handbuch ADHS. Kohlhammer: Stuttgart 2001.
10. Mayes TL, Tao R, Rintelmann JW, et al. Do children and adolescents have differential response rates in placebo-controlled trials of fluoxetine? CNS Spectr 2007; 12(2): 147-54.
11. Usala T, Clavenna A, Zuddas A, et al. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur Neuropsychopharmacol 2008; 18(1): 62-73.
12. Tsapakis EM, Soldani F, Tondo L, et al. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry 2008; 193(1): 10-7.
13. van Praag H, Schinder AF, Christie BR, et al. Functional neurogenesis in the adult hippocampus. Nature 2002; 415(6875): 1030-4.
14. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59(12): 1116-27.
15. Goodyer IM. Emanuel Miller Lecture: early onset depressions--meanings, mechanisms and processes. J Child Psychol Psychiatry 2008; 49(12): 1239-56.
16. White KJ, Walline CC, Barker EL. Serotonin transporters: implications for antidepressant drug development. AAPS J 2005; 7(2): E421-33.
17. Bock N, Quentin DJ, Huther G, et al. Very early treatment with fluoxetine and reboxetine causing long-lasting change of the serotonin but not the noradrenaline transporter in the frontal cortex of rats. World J Biol Psychiatry 2005; 6(2): 107-12.
18. Wegerer V, Moll GH, Bagli M, et al. Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol 1999; 9(1): 13-24; discussion 25-6.
19. Karpova NN, Lindholm J, Pruunsild P, et al. Long-lasting behavioural and molecular alterations induced by early postnatal fluoxetine exposure are restored by chronic fluoxetine treatment in adult mice. Eur Neuropsychopharmacol 2009; 19(2): 97-108.
20. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38(8): 1083-152.
21. Ibi D, Takuma K, Koike H, et al. Social isolation rearing-induced impairment of the hippocampal neurogenesis is associated with deficits in spatial memory and emotion-related behaviors in juvenile mice. J Neurochem 2008; 105(3): 921-32.
22. Ansorge MS, Zhou M, Lira A, et al. Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 2004; 306(5697): 879-81.
23. Ansorge MS, Morelli E, Gingrich JA. Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice. J Neurosci 2008; 28(1): 199-207.
24. Chang YC, Tzeng SF, Yu L, et al. Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups. Neurobiol Dis 2006; 24(1): 101-13.
25. Taravosh-Lahn K, Bastida C, Delville Y. Differential responsiveness to fluoxetine during puberty. Behav Neurosci 2006; 120(5): 1084-92.
26. Rajkowska G, Miguel-Hidalgo JJ, Wei J, et al. Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45(9): 1085-98.
27. Le Prince G, Copin MC, Hardin H, et al. Neuron-glia interactions: effect of serotonin on the astroglial expression of GFAP and of its encoding message. Brain Res Dev Brain Res 1990; 51(2): 295-8.
28. Cotter D, Mackay D, Landau S, et al. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001; 58(6): 545-53.
29. Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004; 56(9): 640-50.
30. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000; 48(8): 766-77.
31. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008; 64(10): 863-70.
32. Azmitia EC, Gannon PJ, Kheck NM, et al. Cellular localization of the 5-HT1A receptor in primate brain neurons and glial cells. Neuropsychopharmacology 1996; 14(1): 35-46.
33. Czeh B, Simon M, Schmelting B, et al. Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment. Neuropsychopharmacology 2006; 31(8): 1616-26.
34. Homberg JR, Olivier JD, Smits BM, et al. Characterization of the serotonin transporter knockout rat: a selective change in the functioning of the serotonergic system. Neuroscience 2007; 146(4): 1662-76.
35. Olivier JD, Van Der Hart MG, Van Swelm RP, et al. A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders. Neuroscience 2008; 152(3): 573-84.
36. Norcross M, Mathur P, Enoch AJ, et al. Effects of adolescent fluoxetine treatment on fear-, anxiety- or stress-related behaviors in C57BL/6J or BALB/cJ mice. Psychopharmacology (Berl) 2008; 200(3): 413-24.
37. Holick KA, Lee DC, Hen R, Dulawa SC. Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008; 33(2): 406-17.
38. Sanchez-Mora C, Ribases M, Ramos-Quiroga JA, et al. Metaanalysis of brain-derived neurotrophic factor p.Val66Met in adult ADHD in four European populations. Am J Med Genet B Neuropsychiatr Genet 2010; 153B(2): 512-23.
39. Stevens SE, Kumsta R, Kreppner JM, et al. Dopamine transporter gene polymorphism moderates the effects of severe deprivation on ADHD symptoms: developmental continuities in gene-environment interplay. Am J Med Genet B Neuropsychiatr Genet 2009; 150B(6): 753-61.
40. Doyle C, Brookes K, Simpson J, et al. Replication of an association of a promoter polymorphism of the dopamine transporter gene and attention deficit hyperactivity disorder. Neurosci Lett 2009; 462(2): 179-81.
41. Banerjee E, Sinha S, Chatterjee A, et al. No causal role for the G482T and G689T polymorphisms in translation regulation of serotonin transporter (SLC6A4) or association with attention-deficithyperactivity disorder (ADHD). Neurosci Lett 2009; 454(3): 244-8.
42. Kim CH, Hahn MK, Joung Y, et al. A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA 2006; 103(50): 19164-9.
43. Purper-Ouakil D, Wohl M, Orejarena S, et al. Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3). Am J Med Genet B Neuropsychiatr Genet 2008; 147B(8): 1425-30.
44. Tharoor H, Lobos EA, Todd RD, et al. Association of dopamine, serotonin, and nicotinic gene polymorphisms with methylphenidate response in ADHD. Am J Med Genet B Neuropsychiatr Genet 2008; 147B(4): 527-30.
45. Smith KM, Bauer L, Fischer M, et al. Identification and characterization of human NR4A2 polymorphisms in attention deficit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 2005; 133B(1): 57-63.
46. Fischer JF, Cho AK. Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 1979; 208(2): 203-9.
47. Pierce RC, Kalivas PW. Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. J Neurosci 1997; 17(9): 3254-61.
48. Seeman P, Madras BK. Anti-hyperactivity medication: methylphenidate and amphetamine. Mol Psychiatry 1998; 3(5): 386-96.
49. Trinh JV, Nehrenberg DL, Jacobsen JP, et al. Differential psychostimulant-induced activation of neural circuits in dopamine transporter knockout and wild type mice. Neuroscience 2003; 118(2): 297-310.
50. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27(5): 699-711.
51. Durell T, Adler L, Wilens T, et al. Atomoxetine treatment for ADHD: younger adults compared with older adults. J Atten Disord 2009.
52. Takahashi M, Takita Y, Yamazaki K, et al. A randomized, doubleblind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009; 19(4): 341-50.
53. Valentini V, Frau R, Di Chiara G. Noradrenaline transporter blockers raise extracellular dopamine in medial prefrontal but not parietal and occipital cortex: differences with mianserin and clozapine. J Neurochem 2004; 88(4): 917-27.
54. Moron JA, Brockington A, Wise RA, et al. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22(2): 389-95.
55. Yamamoto BK, Novotney S. Regulation of extracellular dopamine by the norepinephrine transporter. J Neurochem 1998; 71(1): 274-80.
56. Devoto P, Flore G, Pira L, et al. Alpha2-adrenoceptor mediated corelease of dopamine and noradrenaline from noradrenergic neurons in the cerebral cortex. J Neurochem 2004; 88(4): 1003-9.
57. Moll GH, Hause S, Ruther E, et al. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001; 11(1): 15-24.
58. Gray JD, Punsoni M, Tabori NE, et al. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci 2007; 27(27): 7196-207.
59. Grund T, Teuchert-Noodt G, Busche A, et al. Administration of oral methylphenidate during adolescence prevents suppressive development of dopamine projections into prefrontal cortex and amygdala after an early pharmacological challenge in gerbils. Brain Res 2007; 1176: 124-32.
60. Mueller D, Chapman CA, Stewart J. Amphetamine induces dendritic growth in ventral tegmental area dopaminergic neurons in vivo via basic fibroblast growth factor. Neuroscience 2006; 137(3): 727-35.
61. Yin HS, Tan HW. Effects of amphetamine on serotoninergic and GABAergic expression of developing brain. Neurotoxicol Teratol 2007; 29(2): 264-72.
62. Yin HS, Chen CT, Lin TY. Age- and region-dependent alterations in the GABAergic innervation in the brain of rats treated with amphetamine. Int J Neuropsychopharmacol 2004; 7(1): 35-48.
63. Mukda S, Kaewsuk S, Ebadi M, et al. Amphetamine-induced changes in dopamine receptors in early postnatal rat brain. Dev Neurosci 2009; 31(3): 193-201.
64. Lagace DC, Yee JK, Bolanos CA, et al. Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol Psychiatry 2006; 60(10): 1121-30.
65. Chase T, Carrey N, Soo E, et al. Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neuroscience 2007; 144(3): 969-84.
66. Chase TD, Carrey N, Brown RE, et al. Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Brain Res Dev Brain Res 2005; 157(2): 181-91.
67. Banerjee PS, Aston J, Khundakar AA, et al. Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediate-early gene Arc in the juvenile and adult brain. Eur J Neurosci 2009; 29(3): 465-76.
68. Meredith GE, Callen S, Scheuer DA. Brain-derived neurotrophic factor expression is increased in the rat amygdala, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res 2002; 949(1-2): 218-27.
69. Carlezon WA, Jr., Mague SD, Andersen SL. Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry 2003; 54(12): 1330-7.
70. McFadyen MP, Brown RE, Carrey N. Subchronic methylphenidate administration has no effect on locomotion, emotional behavior, or water maze learning in prepubertal mice. Dev Psychobiol 2002; 41(2): 123-32.
71. Mague SD, Andersen SL, Carlezon WA, Jr. Early developmental exposure to methylphenidate reduces cocaine-induced potentiation of brain stimulation reward in rats. Biol Psychiatry 2005; 57(2): 120-5.
72. Bolanos CA, Barrot M, Berton O, et al. Methylphenidate treatment during pre- and periadolescence alters behavioral responses to emotional stimuli at adulthood. Biol Psychiatry 2003; 54(12): 1317-29.
73. Andersen SL, Arvanitogiannis A, Pliakas AM, et al. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 2002; 5(1): 13-4.
74. Dow-Edwards DL, Weedon JC, Hellmann E. Methylphenidate improves performance on the radial arm maze in periadolescent rats. Neurotoxicol Teratol 2008; 30(5): 419-27.
75. Bethancourt JA, Camarena ZZ, Britton GB. Exposure to oral methylphenidate from adolescence through young adulthood produces transient effects on hippocampal-sensitive memory in rats. Behav Brain Res 2009; 202(1): 50-7.
76. Hussar DA. New drugs of 2003. J Am Pharm Assoc (2003) 2004; 44(2): 168-206; quiz 207-10.
77. van der Kooij MA, Glennon JC. Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci Biobehav Rev 2007; 31(4): 597-618.
78. Kostrzewa RM, Kostrzewa JP, Kostrzewa RA, et al. Pharmacological models of ADHD. J Neural Transm 2008; 115(2): 287-98.
79. Russell VA. Neurobiology of animal models of attention-deficit hyperactivity disorder. J Neurosci Methods 2007; 161(2): 185-98.
80. Sagvolden T, Russell VA, Aase H, et al. Rodent models of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57(11): 1239-47.
81. Sagvolden T. Behavioral validation of the spontaneously hypertensive rat (SHR) as an animal model of attention-deficit/hyperactivity disorder (AD/HD). Neurosci Biobehav Rev 2000; 24(1): 31-9.
82. Sagvolden T, Dasbanerjee T, Zhang-James Y, et al. Behavioral and genetic evidence for a novel animal model of attentiondeficit/hyperactivity disorder predominantly inattentive subtype. Behav Brain Funct 2008; 4: 56.
83. Roessner V, Sagvolden T, Dasbanerjee T, et al. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the ADHD combined type, but not to the same extent in one of the ADHD inattentive type. Neuroscience 2010; 167(4): 1183-91.
84. Roessner V, Manzke T, Becker A, et al. Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD. World J Biol Psychiatry 2009; 10(4 pt 2): 581-5.
85. Kuczenski R, Segal DS. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 2005; 57(11): 1391-6.
86. Bock N, Moll GH, Wicker M, et al. Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system. Pharmacopsychiatry 2004; 37(4): 163-7.
87. Nestler EJ. Molecular neurobiology of addiction. Am J Addict 2001; 10(3): 201-17.
88. Baghai TC, Moller HJ, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des 2006; 12(4): 503-515.
89. Crowley JJ, Lucki I. Opportunities to discover genes regulating depression and antidepressant response from rodent behavioral genetics. Curr Pharm Des 2005; 11(2): 157-169.
90. Mitchell PJ, Redfern PH. Animal models of depressive illness: the importance of chronic drug treatment. Curr Pharm Des 2005; 11(2): 171-203.